Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Adults of either sex aged 50 years and older;~* SMH associated with treatment-naive or previously treated wet AMD, including retinal angiomatous proliferation (RAP) and idiopathic polypoidal choroidal vasculopathy (IPCV);~* SMH of at least 1 disc area, involving the fovea, and of sufficient density to obscure RPE detail;~* Written informed consent to participate in the study.Only one eye will be eligible for inclusion in this study.~Exclusion criteria:~* SMH that is known to have been present for greater than 2 weeks duration, as evidenced by history, pre-trial documentation, or fundus appearance;~* Presence of significant vitreous haemorrhage precluding accurate retinal assessment in the study eye;~* Diabetic maculopathy in the study eye;~* Visually significant cataract in the study eye;~* Amblyopia in the study eye;~* Presence of other ocular disease causing concurrent vision loss in the study eye;~* Advanced glaucoma in the study eye (cup-to-disc ratio greater than 0.8);~* Pregnant and or lactating women;~* Women of childbearing potential including those who are not sterilised or at least one year post menopausal;~* Participation in a clinical interventional trial in the preceding 6 months;~* Documented evidence of a visual acuity less than 25 ETDRS letters at three consecutive visits in the study eye, prior to the onset of submacular haemorrhage;~* Participants who are known to have been ineligible for NICE approved ranibizumab therapy prior to the development of the SMH;~* Current treatment for wet age-related macular degeneration with an intravitreal agent other than ranibizumab, bevacizumab or aflibercept;~* Patients who, in the opinion of the Investigator, would not be willing or able to comply with the study protocol, including posturing requirements.~* Patients who show insufficient understanding of the clinical trial or treatment options.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (A) (Type: SHAM_COMPARATOR): Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
- C3F8 Only Group (B) (Type: EXPERIMENTAL): C3F8 given. Ranibizumab given as standard.
- tPA and C3F8 Group (C) (Type: EXPERIMENTAL): Both C3F8 gas and tPA given. Ranibizumab given as standard.
- tPA Only Group (D) (Type: EXPERIMENTAL): tPA given. Ranibizumab given as standard.

Based on this trial design, predict the completion outcome and termination type (if applicable).